View Older Stories View More Recent Stories

Oct 22, 2023 10:30AM Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Lin
Oct 16, 2023 08:00AM Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023
Oct 12, 2023 08:00AM Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
Sep 22, 2023 05:29AM Seagen (SGEN) Reports PADCEV and KEYTRUDA Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 T
Sep 22, 2023 05:00AM PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in
Sep 5, 2023 05:35AM Seagen (SGEN) and Genmab (GMAB) Report TIVDAK Met its Primary Endpoint of Improved Overall Survival
Sep 4, 2023 03:00PM Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherap
Sep 4, 2023 03:00PM Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
Aug 16, 2023 08:00AM Seagen (SGEN) Phase 3 Trial of TUKYSA with ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival
Aug 16, 2023 08:00AM Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treat
Aug 2, 2023 08:00AM Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
Jul 12, 2023 08:00AM Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023
Jun 20, 2023 08:30AM Seagen (SGEN) Reports Positive Phase 3 Data of ADCETRIS with Modified Chemo Regimen
Jun 20, 2023 08:30AM Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standar
Jun 15, 2023 05:59AM Seagen (SGEN) Reports Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS
Jun 14, 2023 08:31PM Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
Jun 13, 2023 04:45AM Seagen (SGEN) Reports ADCETRIS Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate
Jun 13, 2023 03:01AM Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin
May 30, 2023 03:22PM Seagen (SGEN) Stockholders Approve Acquisition by Pfizer (PFE)
May 30, 2023 03:22PM Seagen Stockholders Approve Acquisition by Pfizer
Apr 27, 2023 08:00AM Seagen Reports First Quarter 2023 Financial Results
Apr 26, 2023 10:48AM Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
Apr 7, 2023 08:00AM Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
Apr 3, 2023 05:01PM FDA Approves Merck’s (MRK) KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Apr 3, 2023 05:00PM FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
Apr 3, 2023 05:00PM FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
Mar 14, 2023 04:30PM Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
Mar 13, 2023 06:45AM Pfizer (PFE) Acquires Seagen (SGEN) for $43B or $229/sh
Mar 13, 2023 06:45AM Pfizer Invests $43 Billion to Battle Cancer
Mar 13, 2023 06:45AM Pfizer Invests $43 Billion to Battle Cancer
Mar 9, 2023 06:30PM Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Uro
Mar 9, 2023 06:30PM Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Uroth
Feb 27, 2023 08:00AM Seagen to Present at the Cowen 43rd Annual Health Care Conference
Feb 15, 2023 04:02PM Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 13, 2023 05:00PM Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
Jan 19, 2023 02:22PM Seagen (SGEN) Announces FDA Accelerated Approval of TUKYSA in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Jan 19, 2023 02:21PM Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Jan 19, 2023 08:00AM Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
Dec 20, 2022 08:00AM Seagen to Present at the J.P. Morgan Healthcare Conference
Dec 20, 2022 06:47AM Merck (MRK), Seagen (SGEN) and Astellas Announce FDA Acceptance of sBLA for PADCEV with KEYTRUDA
Dec 20, 2022 06:45AM Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advance
Dec 20, 2022 06:45AM Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of
Dec 12, 2022 10:00AM Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
Dec 1, 2022 08:30AM Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
Nov 10, 2022 01:14PM Seagen (SGEN) Announces FDA Approval for New ADCETRIS Indication
Nov 10, 2022 01:12PM Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
Nov 10, 2022 09:00AM Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
Nov 10, 2022 07:05AM Seagen (SGEN) Appoints Sandra M. Swain to its Board
Nov 10, 2022 07:05AM Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
Nov 10, 2022 07:00AM Seagen (SGEN) Appoints David R. Epstein as CEO and Director
View More Recent Stories View Older Stories